Skip to main content

Exiqon, Integrated DNA Technologies Ink Locked Nucleic Acid Licensing Deal

NEW YORK, Jan. 5 (GenomeWeb News) - Denmark's Exiqon has licensed certain rights to its locked nucleic acid technology to Integrated DNA Technologies (IDT), the companies said today.

 

Under the terms of the deal, IDT has non-exclusive rights to manufacture and sell locked nucleic acid oligonucleotides for the genomics research market and will receive access to certain Exiqon know-how related to the technology.

 

Financial terms of the arrangement were not disclosed.

 

According to the companies, a locked nucleic acid is a proprietary nucleic acid analog that is easily incorporated into synthetic DNA oligos. Locked nucleic acid probes, they added, have successfully been used in both RT-PCR-based expression profiling and SNP genotyping assays, as well as in expression microarrays and siRNA oligos for target validation.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.